These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30869300)

  • 1. [Cardiac and vascular toxicity of chemotherapies].
    Ederhy S; Ancedy Y; Champiat S; Lopez-Trabada-Ataz D; Dulery R; Cohen A
    Rev Prat; 2018 Mar; 68(3):326-329. PubMed ID: 30869300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
    Nelson-Veniard M; Thambo JB
    Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
    Agunbiade TA; Zaghlol RY; Barac A
    Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical spectrum of anthracycline antibiotic cardiotoxicity.
    Bristow MR; Billingham ME; Mason JW; Daniels JR
    Cancer Treat Rep; 1978 Jun; 62(6):873-9. PubMed ID: 667861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
    Kobza C
    Clin J Oncol Nurs; 2021 Jun; 25(3):259-266. PubMed ID: 34019025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
    Pai VB; Nahata MC
    Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early detection of cancer therapeutics-related cardiac dysfunction].
    Potier A; Ederhy S; Ancedy Y; Etienney A; Soulat-Dufour L; Chauvet M; Hollebecque A; Adavane-Scheuble S; Boccara F; Soria JC; Cohen A
    Bull Cancer; 2016; 103(7-8):667-73. PubMed ID: 27417336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology of anthracycline cardiotoxicity.
    Mele D; Tocchetti CG; Pagliaro P; Madonna R; Novo G; Pepe A; Zito C; Maurea N; Spallarossa P
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e3-e11. PubMed ID: 27755237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiotoxicity as undesired side effect in the treatment of breast cancer].
    Gramatyka M
    Postepy Hig Med Dosw (Online); 2014 May; 68():483-97. PubMed ID: 24864100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardio-oncology: cardiovascular complications of cancer therapy.
    Henning RJ; Harbison RD
    Future Cardiol; 2017 Jul; 13(4):379-396. PubMed ID: 28660778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
    Barrett-Lee PJ; Dixon JM; Farrell C; Jones A; Leonard R; Murray N; Palmieri C; Plummer CJ; Stanley A; Verrill MW
    Ann Oncol; 2009 May; 20(5):816-27. PubMed ID: 19153118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic possibilities of late cardiotoxic sequelae of chemotherapy with anthracyclines].
    Elbl L; Hrstková H; Chaloupka V; Novotný J
    Vnitr Lek; 2002 Oct; 48(10):981-8. PubMed ID: 16737150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Severe heart failure in consequence of late anthracycline-induced cardiotoxicity--case report].
    Urbanová D; Bubanská E; Hrebík M; Mladosievicová B
    Klin Onkol; 2009; 22(1):34-7. PubMed ID: 19534438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
    Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline-induced cardiomyopathy.
    Keefe DL
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):2-7. PubMed ID: 11552224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.